Sarah Glewis

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

Affordable Care Act

Top Venues

British journal of cancer

Clinical and translational science

Acta oncologica (Stockholm, Sweden)

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah Glewis, Senthil Lingaratnam, Mei Krishnasamy, Jennifer H Martin, Jeanne Tie, Marliese Alexander, Michael Michael
Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Sarah Glewis, Mei Krishnasamy, Senthil Lingaratnam, Sam Harris, Craig Underhill, Chloe Georgiou, Mark Warren, Robert Campbell, Maarten IJzerman, Mussab Fagery, Ian Campbell, Jennifer H Martin, Jeanne Tie, Marliese Alexander, Michael Michael
Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey. Clinical and translational science (2023)
Sarah Glewis, Marliese Alexander, Senthil Lingaratnam, Benjamin Lee, Ian Campbell, Mei Krishnasamy, Maarten IJzerman, Mussab Fagery, Sam Harris, Chloe Georgiou, Craig Underhill, Mark Warren, Robert Campbell, Jennifer Martin, Jeanne Tie, Michael Michael
Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial. Acta oncologica (Stockholm, Sweden) 61 (9) (2022)
Sarah Glewis, Marliese Alexander, Muhammad N H Khabib, Annabelle Brennan, Smaro Lazarakis, Jennifer Martin, Jeanne Tie, Senthil Lingaratnam, Michael Michael
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. British journal of cancer 127 (1) (2022)